Matches in SemOpenAlex for { <https://semopenalex.org/work/W3033011894> ?p ?o ?g. }
- W3033011894 abstract "Abstract Understanding resistance mechanisms to targeted therapies and immune checkpoint blockade in mutant KRAS lung cancers is critical to developing novel combination therapies and improving patient survival. Here, we show that MEK inhibition enhanced PD-L1 expression while PD-L1 blockade upregulated MAPK signaling in mutant KRAS lung tumors. Combined MEK inhibition with anti-PD-L1 synergistically reduced lung tumor growth and metastasis, but tumors eventually developed resistance to sustained combinatorial therapy. Multi-platform profiling revealed that resistant lung tumors have increased infiltration of Th17 cells, which secrete IL-17 and IL-22 cytokines to promote lung cancer cell invasiveness and MEK inhibitor resistance. Antibody depletion of IL-17A in combination with MEK inhibition and PD-L1 blockade markedly reduced therapy-resistance in vivo . Clinically, increased expression of Th17-associated genes in melanoma patients treated with PD-1 blockade predicted poorer overall survival and response. Our study validates a triple combinatorial therapeutic strategy to overcome resistance to combined MEK inhibitor and PD-L1 blockade." @default.
- W3033011894 created "2020-06-12" @default.
- W3033011894 creator A5007057062 @default.
- W3033011894 creator A5008700269 @default.
- W3033011894 creator A5010884206 @default.
- W3033011894 creator A5017623728 @default.
- W3033011894 creator A5020175596 @default.
- W3033011894 creator A5029229347 @default.
- W3033011894 creator A5034382901 @default.
- W3033011894 creator A5037677450 @default.
- W3033011894 creator A5040689615 @default.
- W3033011894 creator A5042916524 @default.
- W3033011894 creator A5067755477 @default.
- W3033011894 creator A5078178224 @default.
- W3033011894 creator A5089771018 @default.
- W3033011894 date "2020-06-07" @default.
- W3033011894 modified "2023-09-25" @default.
- W3033011894 title "Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers" @default.
- W3033011894 cites W1577577364 @default.
- W3033011894 cites W1933761723 @default.
- W3033011894 cites W1982929992 @default.
- W3033011894 cites W1994469036 @default.
- W3033011894 cites W1996863944 @default.
- W3033011894 cites W2024490058 @default.
- W3033011894 cites W2027146979 @default.
- W3033011894 cites W2028195000 @default.
- W3033011894 cites W2029281176 @default.
- W3033011894 cites W2059129804 @default.
- W3033011894 cites W2070769098 @default.
- W3033011894 cites W2074067501 @default.
- W3033011894 cites W2081098333 @default.
- W3033011894 cites W2081990599 @default.
- W3033011894 cites W2094207365 @default.
- W3033011894 cites W2102059693 @default.
- W3033011894 cites W2128792706 @default.
- W3033011894 cites W2137119270 @default.
- W3033011894 cites W2139008734 @default.
- W3033011894 cites W2146512944 @default.
- W3033011894 cites W2156353875 @default.
- W3033011894 cites W2160586729 @default.
- W3033011894 cites W2173565120 @default.
- W3033011894 cites W2203736446 @default.
- W3033011894 cites W2256481109 @default.
- W3033011894 cites W2289851792 @default.
- W3033011894 cites W2512614851 @default.
- W3033011894 cites W2591431100 @default.
- W3033011894 cites W2610919492 @default.
- W3033011894 cites W2613467753 @default.
- W3033011894 cites W2761575992 @default.
- W3033011894 cites W2884332748 @default.
- W3033011894 cites W2892890999 @default.
- W3033011894 cites W2898290288 @default.
- W3033011894 cites W2912967789 @default.
- W3033011894 cites W2914170573 @default.
- W3033011894 cites W2922513518 @default.
- W3033011894 cites W2929513598 @default.
- W3033011894 cites W2948716731 @default.
- W3033011894 cites W2951426376 @default.
- W3033011894 doi "https://doi.org/10.1101/2020.06.07.136366" @default.
- W3033011894 hasPublicationYear "2020" @default.
- W3033011894 type Work @default.
- W3033011894 sameAs 3033011894 @default.
- W3033011894 citedByCount "0" @default.
- W3033011894 crossrefType "posted-content" @default.
- W3033011894 hasAuthorship W3033011894A5007057062 @default.
- W3033011894 hasAuthorship W3033011894A5008700269 @default.
- W3033011894 hasAuthorship W3033011894A5010884206 @default.
- W3033011894 hasAuthorship W3033011894A5017623728 @default.
- W3033011894 hasAuthorship W3033011894A5020175596 @default.
- W3033011894 hasAuthorship W3033011894A5029229347 @default.
- W3033011894 hasAuthorship W3033011894A5034382901 @default.
- W3033011894 hasAuthorship W3033011894A5037677450 @default.
- W3033011894 hasAuthorship W3033011894A5040689615 @default.
- W3033011894 hasAuthorship W3033011894A5042916524 @default.
- W3033011894 hasAuthorship W3033011894A5067755477 @default.
- W3033011894 hasAuthorship W3033011894A5078178224 @default.
- W3033011894 hasAuthorship W3033011894A5089771018 @default.
- W3033011894 hasBestOaLocation W30330118941 @default.
- W3033011894 hasConcept C104317684 @default.
- W3033011894 hasConcept C121608353 @default.
- W3033011894 hasConcept C126322002 @default.
- W3033011894 hasConcept C127561419 @default.
- W3033011894 hasConcept C143998085 @default.
- W3033011894 hasConcept C170493617 @default.
- W3033011894 hasConcept C184235292 @default.
- W3033011894 hasConcept C203014093 @default.
- W3033011894 hasConcept C2776256026 @default.
- W3033011894 hasConcept C2776999253 @default.
- W3033011894 hasConcept C2777658100 @default.
- W3033011894 hasConcept C2777701055 @default.
- W3033011894 hasConcept C2778468042 @default.
- W3033011894 hasConcept C2780851360 @default.
- W3033011894 hasConcept C2781187634 @default.
- W3033011894 hasConcept C2781230642 @default.
- W3033011894 hasConcept C2781249067 @default.
- W3033011894 hasConcept C502942594 @default.
- W3033011894 hasConcept C526805850 @default.
- W3033011894 hasConcept C55493867 @default.
- W3033011894 hasConcept C57074206 @default.
- W3033011894 hasConcept C71924100 @default.